A Phase 3 Open-Label, Randomized Multicenter Study to Evaluate Efficacy and Safety of Secukinumab in Pediatric Patients with Moderate to Severe Plaque Psoriasis: 24-Week Results.
Journal of the American Academy of Dermatology（2021）
Key words
moderate to severe plaque psoriasis,pediatric psoriasis,secukinumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined